Personalized TMS for Early-Stage Alzheimer's Disease
Author Information
Author(s): Kashyap Bhavani, Hanson Leah R., Gustafson Sally K., Barclay Terry, Howe Clarissa M., Sherman Samantha J., Hungs Marcel, Rosenbloom Michael H.
Primary Institution: HealthPartners Institute
Hypothesis
Can fc-rs-fMRI guided TMS improve cognitive function in early-stage Alzheimer's disease?
Conclusion
The study found that while there were no significant changes in brain connectivity, participants showed improvement in attention scores after treatment.
Supporting Evidence
- Participants showed improvement on the attention index score after treatment.
- All participants completed the study without dropping out.
- Three participants experienced mild adverse effects related to treatment.
Takeaway
This study tested a new way to help people with early Alzheimer's by using brain scans to guide treatment, and some people got better at paying attention.
Methodology
Participants received personalized TMS treatment based on fc-rs-fMRI imaging over 2 weeks, with assessments before and after treatment.
Potential Biases
The absence of a sham control group may introduce bias in interpreting the treatment effects.
Limitations
The study had a small sample size, lacked a control group, and the treatment duration may not have been sufficient to capture all effects.
Participant Demographics
{"mean_age":67.6,"sex_distribution":{"male":7,"female":3},"race":"White","ethnicity":"Not Hispanic/Latino"}
Statistical Information
P-Value
0.01
Statistical Significance
p=0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website